Skip to main
ETON
ETON logo

ETON Stock Forecast & Price Target

ETON Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Eton Pharmaceuticals has demonstrated consistent year-over-year revenue growth, with an estimated increase of 20% to $38.1 million in 2024, followed by a remarkable projected growth of 170% to $103.7 million in 2025. The company is also focused on pipeline expansion, with anticipated revenue generation from new products like Amglidia, which is expected to contribute $4.2 million in 2027 and grow to $16.0 million by 2032, contingent upon FDA approval. Furthermore, Eton's management has successfully adjusted revenue expectations based on projected price increases, indicating a positive outlook driven by effective portfolio execution.

Bears say

Eton Pharmaceuticals Inc. is poised to incur a significant financial burden with $30.7 million in upfront payments for the acquisitions of Increlex and Galzin, which may strain its liquidity and operational resources. Additionally, management's belief that these products are priced lower than competing drugs raises concerns about potential revenue and margin challenges in a competitive market. This combination of substantial acquisition costs and pricing pressures creates a negative outlook for the company's financial health and growth potential.

ETON has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eton Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eton Pharmaceuticals Inc (ETON) Forecast

Analysts have given ETON a Strong Buy based on their latest research and market trends.

According to 3 analysts, ETON has a Strong Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eton Pharmaceuticals Inc (ETON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.